Carla Biesdorf

7PUBLICATIONS
35CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 14, 2026
Population Pharmacokinetics and Exposure-Response Analyses to Support Cofetuzumab Pelidotin (ABBV-647) Dose Optimization in Non-Small Cell Lung Cancer Patients.

|May 10, 2026
Semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With Myelofibrosis.

|May 01, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

|Nov 30, 2023
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.

Carla Biesdorf, Xiaowen Guan, Satya R Siddani

|Jan 31, 2023
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.

Stephen K Tahir, Emiliano Calvo, Benedito A Carneiro

|Nov 18, 2020
Informing Development of Bispecific Antibodies Using Physiologically Based Pharmacokinetic-Pharmacodynamic Models: Current Capabilities and Future Opportunities.

John P Gibbs, Theresa Yuraszeck, Carla Biesdorf

Pageof 2

Frequent Collaborators

3 joint publications

Akshanth R Polepally

3 joint publications

Rajeev M Menon

2 joint publications

Benjamin Engelhardt

2 joint publications

Kevin J Freise